Do you have a blood cancer or have received a stem cell transplant and have been diagnosed with a respiratory infection? If so, you might be eligible to take part in a study to see if an experimental treatment is effective at reducing the severity of the respiratory infection.

The standard treatment for newly-diagnosed multiple myeloma (NDMM) is autologous stem cell transplantation (ASCT). For this procedure, a patient's own healthy, blood-forming cells are collected. The patient then receives high-dose chemotherapy or radiation to kill the cancer cells. Then their healthy cells are returned to their body to recover. While ASCT is effective for many patients, it has significant side effects and may not be the best option for every patient with NDMM. In this research study, participants will receive one of two (2) study treatments: a new regimen of elranatamab plus daratumumab or a conventional regimen of ASCT plus lenalidomide and daratumumab. The delayed use of ASCT, as explored in this research study, is experimental and not standard-of-care.

We are conducting a study to see how money concerns can affect people with advanced cancer. The goal of this study is to see if monthly check-ins about money problems help ease financial worries for adults with advanced cancer who are getting treatment. If you or someone you know is dealing with money stress while having cancer, we'd like to hear from you. Your participation can help improve care for future patients.

The purpose of Substudy 1 is to characterize the safety and tolerability of ABBV-453 in combination with other antimyeloma agents in subjects with Relapsed or Refractory (R/R) Multiple Myeloma (MM) and to determine the recommended Phase 2 doses (RP2D) of ABBV-453 in combination with daratumumab + dexamethasone (Dd) in subjects with R/R MM.

Do you speak Spanish or identify as Hispanic or Latino and have cancer? You can help improve cancer care by sharing your experience. We need patients to complete a one-time survey about your health, background, and cancer treatment. Your input is important and can help others receive better care. Participation involves only a one-time survey, with no required medical tests. ¿Es usted un adulto hispano, latino o de habla hispana con cáncer? Puede ayudar a mejorar la atención del cáncer al compartir su experiencia. Le pedimos a los pacientes que completen una encuesta una sola vez sobre su salud, antecedentes y atención médica durante o después del tratamiento. Su voz es importante y puede ayudar a que otros reciban mejor atención. La participación consiste únicamente en una encuesta, sin pruebas médicas obligatorias.

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

By doing this study, we hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to persons with multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.

The purpose of this study is to find out if an investigational treatment called P-BCMA-ALLO1 is safe and will help treat people with Multiple Myeloma. The study is also being done to determine what dose is safe and effective to treat Multiple Myeloma.

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

We know multiple myeloma can take a long time to diagnose. In this study, we want to better understand how your myeloma was diagnosed so we can identify ways to improve the process.